In yesterday’s Wall Street session, ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares traded at $0.78, up 10.87% from the previous session.
As of this writing, 2 analysts cover ASLAN Pharmaceuticals Limited (NASDAQ:ASLN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $4.00, we find $5.50. Given the previous closing price of $0.70, this indicates a potential upside of 685.71 percent. ASLN stock price is now 48.44% away from the 50-day moving average and 38.96% away from the 200-day moving average. The market capitalization of the company currently stands at $54.94M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
With the price target of $8, Jefferies recently initiated with Buy rating for ASLAN Pharmaceuticals Limited (NASDAQ: ASLN). On January 14, 2019, H.C. Wainwright reiterated its ‘Buy’ rating on the stock by increasing its target price from $12 to quote $8.50.
A total of 0.05% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ASLN stock. A new stake in ASLAN Pharmaceuticals Limited shares was purchased by CAPITAL ANALYSTS, LLC during the first quarter worth $8,000. ROYAL BANK OF CANADA invested $3,000 in shares of ASLN during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in ASLAN Pharmaceuticals Limited valued at approximately $1,000. In total, there are 29 active investors with 31.60% ownership of the company’s stock.
Tuesday morning saw ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) opened at $0.7400. During the past 12 months, ASLAN Pharmaceuticals Limited has had a low of $0.34 and a high of $1.16. As of last week, the company has a debt-to-equity ratio of 0.81, a current ratio of 9.60, and a quick ratio of 9.60. The fifty day moving average price for ASLN is $0.5255 and a two-hundred day moving average price translates $0.5614 for the stock.
The latest earnings results from ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.19, missing analysts’ expectations of -$0.12 by -0.07. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $10.29 million for the quarter, compared to $8.03 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.21 percent.
ASLAN Pharmaceuticals Limited(ASLN) Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
